Compare Aegon Ltd. (AEG) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs Danaher Corporation — how do they compare? Aegon Ltd. trades at $9.42 (market cap $14.01B), while Danaher Corporation trades at $205.09 (market cap $145.83B). The key difference: Danaher Corporation is far larger — about 10.4× Aegon Ltd.'s market cap, and Aegon Ltd. pays the higher dividend (4.94%). Which is the better fit depends on your goals.
| AEG | DHR | |
|---|---|---|
Market Cap | $14.01B | $145.83B |
Sector | Financials | Health |
52-Week High | $9.53 | $242.05 |
52-Week Low | $6.79 | $161.91 |
Enterprise Value | $15.16B | $168.04B |
Dividend Yield | 4.94% | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.45, down 0.84% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company maintains a P/E of 13.54 and P/S of 0.57, indicating potential undervaluation, while a strategic shift to U.S. focus and a $0.25 dividend highlight corporate stability.
The outlook is cautiously optimistic, supported by deleveraging trends and revenue growth projections to $26.9B in 2025. Risks include volatile cash flows and competitive pressures, but analyst consensus leans hold with 50% rating, suggesting steady performance amid transformation efforts.
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
